Replies to post #195192 on Avid Bioservices Inc (CDMO)

[porkchop11]

Data comin Eye, they can't hold...

this back too long...can they? Liver too.

Those some of ur call opts or put now? Wouldnt blame ya either way!

HOLD PP.

Imo.

porkchop11 :0

[Protector]

EBS, no, as per ASM Breast Cancer is still 2nd priority, even BEFORE Liver.

And not only are we good with Docetaxel in breast but also with Immuno.

Specifically, when breast cancer patients were given ch1N11/anti-PD-1 therapies once a week, the growth of tumors was inhibited by 78.7% (p= 0.0048 on day 23) compared to anti-PD-1 used in mono therapy. Additionally, 50% of tumors that were treated with combination therapy were found to either regress or not progress when compared to 0% when using anti-PD-1 alone. Adding to this, the combo treatment administered once weekly achieved a 78% and 81% increase in intratumoral CD4+ and CD8+ T cells. These are two important indicators that reveal that immune cells that fight cancer are indeed present in a tumor’s local environment, when compared to the use of a single agent such as anti-PD-1.

p-value <0.0500 is statistically significant for statisticians
p-value <0.0200 is statistically significant for the FDA
p-value =0.0048 is what these result showed and a relatively SMALL n value.